Macromolecular prodrugs of 5-fluorouracil .2. Enzymatic degradation

被引:27
|
作者
Nichifor, M
Schacht, EH
Seymour, LW
机构
[1] STATE UNIV GHENT,DEPT ORGAN CHEM,BIOMAT & POLYMER RES GRP,B-9000 GHENT,BELGIUM
[2] UNIV BIRMINGHAM,SCH MED,DEPT CLIN ONCOL,BIRMINGHAM B15 2TH,W MIDLANDS,ENGLAND
关键词
5-fluorouracil; prodrug; collagenase; cathepsin; lysosomal enzyme;
D O I
10.1016/0168-3659(95)00141-7
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Polymeric conjugates of 5-fluorouracil were synthesized by the covalent attachment of oligopeptide chains, having a 2-(5-fluorouracil-1-yl)glycine ethyl ester residue at the C-terminus, to poly(ethylene glycol), dextran and poly[N-5-(2-hydroxyethyl)-L-glutamine]. In order to determine their ability to release the free drug by a specific enzymatic process catalyzed by proteinases occurring at the target site, the polymeric conjugates were incubated with three tumor-associated enzymes (collagenase, cathepsin B and cathepsin D) and a mixture of lysosomal enzymes. The enzymes hydrolysed to various extents one or two peptide bonds of the oligopeptide chains attached to polymer carriers. The position and rate of cleavage depended on the enzyme, the composition and configuration of the oligopeptide chain, and on the polymer carrier. PEG[Gly-Phe-Ala-Gly(FU)OEt](2) (1) conjugate was preferentially hydrolysed by collagenase, with the release of tripeptide Phe-Ala-Gly(FU)OR (1). PEG, dextran and PHEG conjugates having Gly-Phe-Gly-Gly(FU)OEt (l,d) as attached oligopeptide chain released free 5-FU in the presence of cathepsin B, with a rate determined by the polymeric carrier: PEG > PHEG > dextran. Finally, PEG conjugates with Gly-Phe-Gly-Gly(FU)OEt (I,d) and Gly-Phe-Phe-Gly(FU)OEt (d) chains released free 5-FU very rapidly in the presence of lysosomal enzymes.
引用
收藏
页码:79 / 92
页数:14
相关论文
共 50 条
  • [21] The synthesis of comb-like polymeric prodrugs of 5-fluorouracil derivatives
    Qiu, Fei
    Yan, Hui
    Wei, Lin
    Diao, Yong
    ADVANCED DESIGN TECHNOLOGY, 2012, 421 : 35 - 38
  • [22] Synthesis and photochemical properties of photoactivated antitumor prodrugs releasing 5-fluorouracil
    Zhang, Z
    Hatta, H
    Ito, T
    Nishimoto, S
    ORGANIC & BIOMOLECULAR CHEMISTRY, 2005, 3 (04) : 592 - 596
  • [23] PRODRUGS OF 5-FLUOROURACIL .5. 1-ALKOXYCARBONYL DERIVATIVES AS POTENTIAL PRODRUG FORMS FOR IMPROVED RECTAL OR ORAL DELIVERY OF 5-FLUOROURACIL
    BUUR, A
    BUNDGAARD, H
    JOURNAL OF PHARMACEUTICAL SCIENCES, 1986, 75 (05) : 522 - 527
  • [24] Chemical and enzymatic hydrolysis of dipeptide derivatives of 5-fluorouracil
    Nichifor, M
    Schacht, EH
    JOURNAL OF CONTROLLED RELEASE, 1997, 47 (03) : 271 - 281
  • [25] EFFECTS OF THE PLASMA-CONCENTRATION OF 5-FLUOROURACIL AND THE DURATION OF CONTINUOUS VENOUS INFUSION OF 5-FLUOROURACIL WITH AN INHIBITOR OF 5-FLUOROURACIL DEGRADATION ON YOSHIDA SARCOMAS IN RATS
    FUJII, S
    SHIMAMOTO, Y
    OHSHIMO, H
    IMAOKA, T
    MOTOYAMA, M
    FUKUSHIMA, M
    SHIRASAKA, T
    JAPANESE JOURNAL OF CANCER RESEARCH, 1989, 80 (02): : 167 - 172
  • [26] Kinetics of 5-Fluorouracil Degradation by Heterogenous TiO2 Photocatalysis
    Constantin, Lucian Alexandru
    Nitoi, Ines
    Cristea, Ionut
    Oancea, Petruta
    REVISTA DE CHIMIE, 2016, 67 (08): : 1447 - 1450
  • [27] COMPARATIVE STUDIES ON METABOLISM OF 2-(TETRAHYDROFURYL)-5-FLUOROURACIL AND 5-FLUOROURACIL
    TOIDE, H
    AKIYOSHI, H
    MINATO, Y
    OKUDA, H
    FUJII, S
    GANN, 1977, 68 (05): : 553 - 560
  • [28] MECHANISM OF TERATOGENIC POTENTIATION OF 5-FLUOROURACIL BY NORMAL PYRIMIDINES .2.
    SCHUMACH.HJ
    WILSON, JG
    JORDAN, RL
    TERATOLOGY, 1968, 1 (02) : 221 - &
  • [29] ENZYMATIC FORMATION OF 5-FLUOROURACIL FROM 1-(TETRAHYDRO-2-FURANYL)-5-FLUOROURACIL (TEGAFUR) IN HUMAN-TUMOR TISSUES
    KONO, A
    HARA, Y
    MATSUSHIMA, Y
    CHEMICAL & PHARMACEUTICAL BULLETIN, 1981, 29 (05) : 1486 - 1488
  • [30] PRODRUGS AS DRUG DELIVERY SYSTEMS .37. PRODRUGS OF 5-FLUOROURACIL .4. HYDROLYSIS KINETICS, BIOACTIVATION AND PHYSICOCHEMICAL PROPERTIES OF VARIOUS N-ACYLOXYMETHYL DERIVATIVES OF 5-FLUOROURACIL
    BUUR, A
    BUNDGAARD, H
    FALCH, E
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1985, 24 (01) : 43 - 60